Weekly Recap | ARKG.US +13.35%, AI healthcare leads genomics themeWeekly Review·Sep 19 at 07:15 AMARKG+2.05%
Weekly Recap | Twist Bioscience +31.26%, signs deal with Lilly TuneLabWeekly Review·Sep 19 at 06:54 AMTWST-0.74%
Weekly Recap | Medicinova +83.43%, most brokers rate it buyWeekly Review·Sep 19 at 06:26 AMMNOV-12.12%
The Nasdaq Biotechnology Index rose over 2.6%, outperforming the broader US stock market. Among constituents, Sarepta Therapeutics surged 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%. Conversely, Aardvark Therapeutics fell 6.10%, ADMA Biologics dropped 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics fell 35.24%Wallstreetcn·Mar 25 at 08:50 PMXBI+2.30%TSHA+2.38%
The Nasdaq Biotechnology Index fell by 1.21%. Among the constituent stocks, Taysha Gene rose by 24.23%, Lexeo Therapeutics rose by 19.85%, and Blueprint Medicines Corp. rose by 10.89%. In contrast, Amicus Therapeutics (FOLD) fell by 13.02%, Phathom Pharma fell by 21.68%, and Arvinas fell by 24.84%Wallstreetcn·May 1, 2025 at 11:16 PMTSHA+2.38%LXEO-0.25%
